文献速递眼底病与葡萄膜炎

湿性AMD贝伐珠单抗12周间隔治疗后渗出复发率

RATES OF EXUDATIVE RECURRENCE FOR EYES WITH INACTIVATED WET AGE-RELATED MACULAR DEGENERATION ON 12-WEEK INTERVAL DOSING WITH BEVACIZUMAB THERAPY.
PubMed 文献 · Retina · 2020-01-01

PURPOSE: To determine the recurrence rate of exudative age-related macular degeneration (wet AMD) in patients on 12-week dosing interval anti-vascular endothelial growth factor (anti-VEGF) bevacizumab therapy.…

要点

  • 12周间隔贝伐珠单抗治疗下无渗出眼年均累积复发率约10%
  • 停用贝伐珠单抗后平均4个月复发风险增加
  • 维持12周间隔治疗仍需监测渗出复发

核心结论

  • 12周间隔贝伐珠单抗治疗的无渗出湿性AMD眼平均每年约10%复发风险。
  • 停用贝伐珠单抗后平均4个月内复发风险增加。

研究设计与样本

  • 评估视力、抗VEGF药物、治疗间隔、治疗时长、停药试验、渗出证据及复发特征。

关键数值与推荐

  • 12周间隔贝伐珠单抗治疗眼平均每年累积复发率10%。

临床怎么用

  • 对已延长至12周间隔贝伐珠单抗且无渗出的湿性AMD眼,应每年警惕约10%复发风险。
  • 停用贝伐珠单抗后4个月内需密切监测渗出复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the recurrence rate of exudative age-related macular degeneration (wet AMD) in patients on 12-week dosing interval anti-vascular endothelial growth factor (anti-VEGF) bevacizumab therapy. METHODS: A retrospective chart review was performed on wet AMD patients treated with anti-VEGF therapy using a "treat-and-extend" methodology at one physician's practice site over 2 years (2012-2014). Charts were evaluated for visual acuity, anti-VEGF agent used, treatment interval, duration of treatment, trials off of anti-VEGF therapy, evidence of exudation, and wet AMD recurrence characteristics. RESULTS: Three hundred and twenty-one wet AMD patients were treated. Fifty-seven eyes were without active exudation by clinical examination or optical coherence tomography (OCT) and were maintained on repeating 12-week interval suppressive anti-VEGF therapy. Sixteen percent (8/49) showed exudation recurrence with an average 10% cumulative recurrence rate per year for eyes on bevacizumab. Eight eyes without active exudation were discontinued off of bevacizumab therapy. Sixty-three percent (5/8) demonstrated recurrence on average 4 months after stopping therapy. CONCLUSION: The findings in this study suggest that if a patient can be extended to 12-week interval bevacizumab therapy, there is on average a 10% chance of recurrence with each successive year. If anti-VEGF therapy is discontinued in these patients, there is an increased chance of recurrence by 4 months.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Hwang RY, Santos D, Oliver SCN, et al. RATES OF EXUDATIVE RECURRENCE FOR EYES WITH INACTIVATED WET AGE-RELATED MACULAR DEGENERATION ON 12-WEEK INTERVAL DOSING WITH BEVACIZUMAB THERAPY. Retina. 2020. PMID: 30649077. doi:10.1097/IAE.0000000000002446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。